These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38187379)

  • 1. Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients.
    Hageman I; Mol F; Atiqi S; Joustra V; Sengul H; Henneman P; Visman I; Hakvoort T; Nurmohamed M; Wolbink G; Levin E; Li Yim AYF; D'Haens G; de Jonge WJ
    Front Immunol; 2023; 14():1303231. PubMed ID: 38187379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.
    Tao W; Concepcion AN; Vianen M; Marijnissen ACA; Lafeber FPGJ; Radstake TRDJ; Pandit A
    Arthritis Rheumatol; 2021 Feb; 73(2):212-222. PubMed ID: 32909363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.
    Oliver J; Nair N; Orozco G; Smith S; Hyrich KL; Morgan A; Isaacs J; Wilson AG; ; Barton A; Plant D
    Arthritis Res Ther; 2021 Mar; 23(1):80. PubMed ID: 33691749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
    Krintel SB; Essioux L; Wool A; Johansen JS; Schreiber E; Zekharya T; Akiva P; Ostergaard M; Hetland ML
    PLoS One; 2012; 7(6):e38539. PubMed ID: 22685579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
    Smith SL; Alexander S; Nair N; Viatte S; Eyre S; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; Plant D; Barton A
    Ann Rheum Dis; 2023 May; 82(5):611-620. PubMed ID: 36810200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.
    Raterman HG; Vosslamber S; de Ridder S; Nurmohamed MT; Lems WF; Boers M; van de Wiel M; Dijkmans BA; Verweij CL; Voskuyl AE
    Arthritis Res Ther; 2012 Apr; 14(2):R95. PubMed ID: 22540992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine Deaminase Gene Polymorphism and Baseline Serum Level of Adenosine Deaminase as a Biomarker of Response to Methotrexate in Rheumatoid Arthritis.
    Gangadharan H; Singh A; Majumder S; Aggarwal A
    J Clin Rheumatol; 2021 Dec; 27(8):e609-e611. PubMed ID: 33044386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
    Vittecoq O; Guillou C; Hardouin J; Gerard B; Berenbaum F; Constantin A; Rincheval N; Combe B; Lequerre T; Cosette P
    Arthritis Res Ther; 2022 Mar; 24(1):72. PubMed ID: 35313956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
    Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
    Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis.
    Rodríguez-Ubreva J; de la Calle-Fabregat C; Li T; Ciudad L; Ballestar ML; Català-Moll F; Morante-Palacios O; Garcia-Gomez A; Celis R; Humby F; Nerviani A; Martin J; Pitzalis C; Cañete JD; Ballestar E
    Ann Rheum Dis; 2019 Nov; 78(11):1505-1516. PubMed ID: 31371305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble urokinase plasminogen activator receptor as a useful biomarker to predict the response to adalimumab in patients with rheumatoid arthritis in a Japanese population.
    Koga T; Okada A; Kawashiri S; Kita J; Suzuki T; Nakashima Y; Tamai M; Satoh K; Origuchi T; Iwamoto N; Yamasaki S; Nakamura H; Migita K; Ida H; Ueki Y; Eguchi K; Kawakami A
    Clin Exp Rheumatol; 2011; 29(5):811-5. PubMed ID: 22011479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
    Badot V; Galant C; Nzeusseu Toukap A; Theate I; Maudoux AL; Van den Eynde BJ; Durez P; Houssiau FA; Lauwerys BR
    Arthritis Res Ther; 2009; 11(2):R57. PubMed ID: 19389237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
    Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A
    Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J; Krintel SB; Carlsen AL; Hetland ML; Johansen JS; Hørslev-Petersen K; Stengaard-Pedersen K; Ellingsen T; Burton M; Junker P; Østergaard M; Heegaard NHH
    J Rheumatol; 2018 Jan; 45(1):53-61. PubMed ID: 29142030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis.
    Palmowski A; Strehl C; Pfeiffenberger M; Häupl T; Schad M; Kallarackal J; Prothmann U; Dammann D; Bonin M; Brandt A; Schneider U; Gaber T; Buttgereit F
    Clin Rheumatol; 2024 Jan; 43(1):511-519. PubMed ID: 37978145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.